Carenostics vs Carna Health
Both attack undiagnosed chronic disease, with kidney disease at the centre of each, and they reach for different instruments. Carenostics reads what is already in the record, including the unstructured notes, to surface patients whose disease is present and unrecognised, with its own model behind it. Carna pairs point of care testing with a platform that ingests laboratory results, device data, record data and social determinants, so the at risk patient can be tested rather than referred into a gap. Carna's interoperability work is real and hard. Its AI claim is not inspectable at all: no architecture, validation method or accuracy figure was located anywhere, alongside no privacy statement or attestation. If you are buying detection intelligence, Carenostics is the one you can interrogate. If you are buying a testing and care pathway, Carna is selling that.
- It reads the record you already have, including unstructured notes, so no new test or device is required to surface an undiagnosed patient.
- The target is chronic disease that is present and unrecognised, which is a different problem from screening a population that has not been tested.
- Model ownership sits with the vendor, so accuracy questions have one accountable party.
- It pairs point of care testing with the platform, so a patient identified as at risk can be tested in the same visit rather than referred and lost.
- The interoperability work is the real and difficult part of the product, ingesting results from laboratories, devices, record systems and social determinants data.
- Its geographic reach is unusually broad for the segment, which matters for an organisation operating outside a single national health system.
Side by Side
| Axis | C Carenostics |
C Carna Health |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Carna describes itself as AI driven across nearly all its material while publishing nothing inspectable: no architecture, feature description, validation methodology or accuracy figure was located across repeated searches, and no health privacy statement, business associate terms or security attestation either. Read the AI claim accordingly. Carenostics publishes no retention or secondary use position.
Both products create downstream cost the vendor does not carry: identifying an at risk patient generates testing, follow up and sometimes treatment, and in a value based contract that near term cost precedes any saving by years.